Breaking News, Collaborations & Alliances

Araxes, Janssen in Cancer Drug Pact

Araxes to receive upfront payment and R&D funding, eligible for royalties

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Araxes Pharma has entered into an exclusive agreement with Janssen Biotech to develop first-in-class therapeutics against a certain target for the treatment of cancer. The drug candidates include a PI3Kdelta/gamma inhibitor, a TORC1/2 inhibitor and a PI3Kalpha inhibitor.    Araxes will advance its program through Phase I to clinical proof-of-concept. Janssen Biotech will then have sole responsibility for the continued development and worldwide commercialization of products arising under the agre...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters